Viral hepatitis B (VHB) and viral hepatitis C (VHC) are public health problems worldwide. 1 According to the World Health Organization (WHO), 350 million people are infected with hepatitis B virus (HBV ) and 130 to 170 million are infected with hepatitis C virus (HCV ) worldwide. 2 VHB and VHC have been named "silent killers" because they remain silent until complications such as cirrhosis and liver cancer. 3, 4 Their prevalences vary between continents and countries. Among Cameroonian adults, prevalences are 8% to 12% for VHB and 3.9% to 13% for VHC. 5 Among Cameroonian pregnant women, Njouom et al 6 reported a prevalence of 1.8% for VHC in 2003 and Fomulu et al 7 reported a prevalence of 7.2% for VHB in 2013.
Introduction
Viral hepatitis B (VHB) and viral hepatitis C (VHC) are public health problems worldwide. 1 According to the World Health Organization (WHO), 350 million people are infected with hepatitis B virus (HBV ) and 130 to 170 million are infected with hepatitis C virus (HCV ) worldwide. 2 VHB and VHC have been named "silent killers" because they remain silent until complications such as cirrhosis and liver cancer. 3, 4 Their prevalences vary between continents and countries. Among Cameroonian adults, prevalences are 8% to 12% for VHB and 3.9% to 13% for VHC. 5 Among Cameroonian pregnant women, Njouom et al 6 reported a prevalence of 1.8% for VHC in 2003 and Fomulu et al 7 reported a prevalence of 7.2% for VHB in 2013.
Without preventive measures, the rate of vertical transmission of HBV is 10% to 40% in the absence of viral replication and 70% to 90% in case of viral replication. 8 The risk is 15% to 45% for HIV and much less for HCV (except in case of coinfection with HIV). 9 Such high rates speak in favor of systematic screening of HBV during pregnancy. Antenatal care is often the only contact of women with health facilities, thus offering a unique opportunity for screening VHB. Knowledge of hepatitis B status during pregnancy allows prevention of vertical transmission. 10 Managing HBV-infected pregnant women gives an opportunity to screen their families. Our goal was to assess prevalences and correlates of VHB and VHC among women attending antenatal clinic.
Materials and Methods
We carried out a cross-sectional analytic study in the Obstetrics and Gynecology Unit of the Yaoundé Central Hospital (YCH) from January 1 2016 to June 30, 2016. The YCH is a referral secondary hospital that has the largest and oldest maternity of the Central Region (Cameroon), with more than 3000 deliveries every year. Most women followed up at the YCH are of low socioeconomic status.
The study population consisted of all pregnant women attending antenatal clinic (ANC) at the YCH during the study period. 
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Were included all women attending ANC at the YCH who gave their written informed consent. We excluded women who, during the process, withdrew their consent and those who were lost to follow-up.
Sampling was consecutive and exhaustive. The Lorenz formula was used to determine the minimal sample size: N = z 2 pq/d 2 , where z is the standard normal deviation at 1.96 (which corresponds to a 95% confidence interval [CI]); p is the prevalence of hepatitis B in pregnant women, estimated at 10.2% in 2015 11 ; q = 1 -p; and d is the degree of precision expected = 0.05. With this formula, our minimal size was 141. But to enhance the validity of our study, we decided to include all pregnant women fulfilling inclusion criteria (ie 360). During the study period, women who had several ANCs were included only once. The interview was face-to-face using a questionnaire with predefined answers.
Ethical clearance (No. 2015/61/ISTM/UD/CE) was obtained from the institutional ethics committee of the University of Douala. And administrative authorization was obtained from the Director of the YCH.
Data Collection
Participants were assigned codes for anonymity purposes. Data were then collected during face-to-face interviews using questionnaires with predefined answers. Sociodemographic parameters were age, marital status, occupation, level of education, and religion. Obstetrical parameters were gestity, parity, and gestational age. Past medico-surgical parameters were blood transfusion, dental care, and surgery. Family history of infection was evaluated with the following: HIV, VHB, and VHC among first-degree relatives. Behavioral risk was assessed through scarifications, multiple sexual partnership, and intravenous drug injections.
Venous blood (3 mL) was sampled to test for VHB and VHC. Blood samples were kept in ambient air to obtain serums that were used to carry rapid diagnostic tests. For HBV, we used DiaSpot HbsAg One step Hepatitis B Surface Antigen (HbsAg) Test Strip Package Insert and for hepatitis C, DiaSpot Hepatitis C virus-antibody (HCV-Ab) Test strips (both manufactured by DiaSpot Diagnostics, USA). Those are immunochromatographic strips for qualitative detection of antibodies and antigens. Their sensitivity and specificity are above 99% and 98%, respectively. All samples with positive tests were sent for quality control by the Pasteur's Institute of Cameroon. Concordance with our results was 100%. Sample carrying hepatitis B virus surface antigen (HbsAg) was further tested for Hbe antigen (HbeAg) and Hbe antibody (HbeAb). Results were disclosed to participants with proper counseling (disease progression, screening of partners, and serovaccination of newborns). All infected women were counseled on the disease and referred for proper specialized care.
Statistical Analysis
Data were analyzed using STATA version 12.0. Frequencies, means, medians, and standard deviations were determined. χ 2 and Fisher exact tests were used to compare frequencies and means. Statistical significance was set at P-value < .05. Unadjusted and adjusted odds ratios (95% confidence interval [CI]) were used to determine association between variables.
Results
Out of the 900 women seen at the antenatal unit, 360 (40%) gave their consent for the study. Mean age was 27.99 ± 5.63 years (range: 15-47 years). Ninety-one (25.3%) participants were primigravidae, and 145 (40.3%) of them were seen during the third trimester of pregnancy.
The seroprevalences of HBV and HCV were 9.4% (34/360) and 1.7% (6/360), respectively. None of the participants were co-infected by HBV and HCV.
Among HbsAg-positive women, 4 (11.8%) tested positive for HbeAg and 9 (26.5%) tested positive for HbeAb. Only 15 participants out of 360 (ie 4.2%) had been vaccinated against HBV. None of the patient's characteristic was associated with hepatitis C infection. Table 1 shows associations of hepatitis B and C infections with patients' characteristics. Table 2 shows associations between hepatitis B infection and risky behaviors. Table 3 shows associations between hepatitis C infection and risky behaviors. Table 4 shows the logistic regression using the two factors initially associated with HBV infections.
Discussion
The seroprevalence of hepatitis B among pregnant women in our study (9.4%) was similar to results previously reported in a rural (9.7%) and in an urban (7.7% and 10.2%) settings in Cameroon. 7, 11, 12 In neighboring Gabon, a seroprevalence of 9.5% among pregnant women was reported in 2008 while Okoth et al 13 reported 9.3% in Kenya in 2006. 14 Among blood donors in Cameroon, the seroprevalence of HBV ranges from 10.8% to 12.4%. 7, 15 Our results are in accordance with WHO statement pointing Cameroon as a country of high endemicity for hepatitis B. 1 In our study, there was no association between blood transfusion, scarifications, family history of hepatitis B infection, and hepatitis B infection.
The seroprevalence of hepatitis C we found among antenatal clinic attenders (1.7%) is similar to the figures reported in the same country (1.8%) and in neighboring Nigeria (1.7%) and Benin (1.9%). 6, 15, 16 However, higher seroprevalences have been reported in distant country such as Ghana (4.6%). 17 An explanation may be found in the fact that investigators in those studies used RNA amplification techniques to screen pregnant women or hepatitis C.
In our study, pregnant women aged between 30 and 34 years were significantly more infected by HBV (OR = 2; 95%CI: 1.82-2.05; Abbreviations: Ci, confidence interval; NA, not applicable; OR, odds ratio. After logistic regression using all initial significative associated factors, multiple sex partners remain the only independent factor associated with HbsAg.
partners was significantly associated with hepatitis B infection (OR = 11.47; 95%CI: 5.11-25.74; Table 4 ). Similar findings were reported in Nigeria and in the Kilimanjaro region. [16] [17] [18] That finding is logical given that hepatitis B is sexually transmitted. Out of the 34 HbsAg-positive pregnant participants, 4 (11.8%) were HbeAg-positive, thus having a 70% to 90% risk of transmitting HBV to their babies. 8 Other researchers reported a wide range of proportions of HbeAg carriers among AbsAg-positive pregnant women in Cameroon: 0% by Kfutwah et al, 19 12.1% by Noubiap et al, 11 41% by Frambo et al, 12 and 21% by Fomulu et al. 7 This heterogeneity needs to be addressed by a nationwide large-scale study. Only 15 (4.2%) of our participants were vaccinated against hepatitis B. This confirms the small coverage previously depicted by Fomulu et al 7 among antenatal clinic attenders in Yaoundé.
As several African authors in recent years, we observed that none of the risk factors were associated with VHC among pregnant women. [20] [21] [22] Nevertheless, blood transfusion was found to be associated with hepatitis C infection during pregnancy in Ghana. 17 
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Although our data were collected in a tertiary center, the results cannot be extrapolated to the whole country. Moreover, a selection bias cannot be excluded. Multicentric studies are needed to have a thorough appraisal of HBV and HCV infections among pregnant women in Cameroon. We did not test for hepatitis B core antibodies which could have helped to decipher between chronic and acute infection on one hand and between naïve and spontaneously healed participants on the other hand. 
Conclusions
Seroprevalences of hepatitis B and C among antenatal clinic attenders at the YCH were 9.4% and 1.7%, respectively. This calls for more actions toward prevention of mother-tochild transmission of hepatitis B. Screening during pregnancy should be systematic and more accessible rather than providerinitiated as it is the case nowadays. Free-of-charge serovaccination against hepatitis B of newborn may also be done at birth instead of only vaccinating at 42 days of live.
